文献速递创面修复美容整形乳房整形与再造

GLP-1激动剂对整形与重建手术后手术部位伤口并发症的影响:倾向匹配队列大型数据库分析

Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis.
PubMed 文献 · Plast Reconstr Surg · 2025-12-09

本研究基于TriNetX国家健康研究数据库,纳入行腹壁皮肤脂肪切除术、腹壁成形术或乳房缩小术的患者,排除糖尿病、外周血管疾病、营养代谢或内分泌疾病、癌症史及吸烟者,采用倾向匹配平衡队列,评估GLP-1受体激动剂使用与术后30天内手术部位伤口感染、裂开或愈合不良的关系。匹配后结果显示,使用GLP-1受体激动剂者的手术部位伤口愈合并发症风险在所有评估术式中均显著更高。

要点

  • GLP-1受体激动剂使用与三类整形手术术后30天伤口并发症风险升高相关。
  • 匹配后腹壁成形术伤口并发症发生率为9.8%对3.6%(P=0.001)。
  • 术前应就减重药物对手术结局的影响进行患者咨询并考虑围手术期管理。

核心结论

  • 使用GLP-1受体激动剂与所有评估术式的手术部位并发症发生率升高相关,提示术前咨询和围手术期管理策略的必要性。

研究设计与样本

  • 基于TriNetX国家健康研究数据库的倾向匹配队列大型数据库分析;纳入行腹壁皮肤脂肪切除术、腹壁成形术或乳房缩小术的患者;排除糖尿病、外周血管疾病、营养代谢或内分泌疾病、癌症史或吸烟者;按GLP-1受体激动剂使用状态比较术后30天内手术部位结局。

主要发现

  • 匹配前及匹配后,使用GLP-1受体激动剂者的手术部位伤口愈合并发症风险均显著高于未使用者。
  • 匹配队列中腹壁皮肤脂肪切除术伤口并发症发生率为4.7%对2.7%(P=0.05)。
  • 匹配队列中腹壁成形术伤口并发症发生率为9.8%对3.6%(P=0.001)。
  • 匹配队列中乳房缩小术伤口并发症发生率为2.6%对1.3%(P=0.035)。

关键数值与推荐

  • 腹壁皮肤脂肪切除术:4.7%对2.7%(P=0.05)。
  • 腹壁成形术:9.8%对3.6%(P=0.001)。
  • 乳房缩小术:2.6%对1.3%(P=0.035)。

临床怎么用

  • 术前应询问患者GLP-1受体激动剂使用情况并就伤口并发症风险进行咨询。
  • 对使用GLP-1受体激动剂者考虑制定围手术期管理计划以改善手术结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained Food and Drug Administration approval for management of type 2 diabetes. However, they have been increasingly used for their weight loss side effect profile. Surgical site wound complications have been observed in patients using these medications (although with a low incidence rate). Given the paucity of literature on weight loss medications and their implications in plastic surgery, this study evaluates the impact of weight loss medication use on postoperative surgical site outcomes in patients undergoing common plastic and reconstructive procedures. METHODS: The TriNetX National Health Research database was queried to identify patients undergoing panniculectomy, abdominoplasty, or breast reduction. Patients with diabetes; peripheral vascular diseases; nutritional, metabolic, or endocrine diseases; a history of cancer; or smoking were excluded. Propensity matching analysis was performed to balance the cohorts. Postoperative outcomes, specifically surgical wound infections, breakdown, or dehiscence within 30 days after the procedure, were assessed based on GLP-1 RA use status. RESULTS: The risk of surgical site wound healing complications in patients taking GLP-1 RAs compared with those not on these medications was statistically significantly higher before cohort matching as well as after matching. Matched cohort results were as follows: 4.7% versus 2.7% for panniculectomy ( P = 0.05), 9.8% versus 3.6% for abdominoplasty ( P = 0.001), and 2.6% versus 1.3% for breast reduction ( P = 0.035), respectively. CONCLUSIONS: Use of GLP-1 RAs was associated with higher rates of surgical site complications across all evaluated procedures. This underscores the necessity of patient counseling regarding the implications of these weight loss medications before surgery, along with the potential need for a strategic perioperative management plan to enhance surgical outcomes.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Lee CC, Newland M, Yau A, et al. Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis. Plast Reconstr Surg. 2025. PMID: 41364427. doi:10.1097/PRS.0000000000012703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。